Is There Any Research on Memodyne? A Fact Check of the Claims

Imagine a fact-checker with a red pen and a pile of Memodyne pages. The job is not to prove the product bad. It is to ask of each claim: who said it, where is the evidence, and does the evidence fit the product on the shelf?

That is this page. We build a ledger of claims, check the logos that look like science, look at what the ingredient studies measured, and say what kind of research would change our minds. We cite only the public sources the site already uses.

The ledger lists a claim, where it is printed and what we could confirm. Marketing only means we found no source behind it.

Six of the seven lines have no evidence we can open. The seventh, the label wording, is allowed because it describes normal function and carries the FDA statement (FDA, Structure/Function Claims).

There is real research on single ingredients. It just answers other questions.

Sources: (RxList, L-Arginine (supplement monograph)) (Avicenna J Phytomed 2019, Barkhidarian et al., L-citrulline and blood pressure meta-analysis) (ISSN position stand: Beta-Alanine (2015)) (Nutrients 2023, Ostfeld et al., beta-alanine and cognition in older adults) (NIH ODS, Niacin (health professional)). One drug-information source lists age-related memory loss for arginine and rates the evidence as insufficient to rate.

Notice what is common to every row. The studied dose is much larger than the capsule, and the outcome is not memory or focus. That is the gap, and it is why we say the research is real but does not speak for this product.

FTC guidance says health claims need competent and reliable science, usually randomized human trials, and that an advertiser should compare its own dose and formula with the one studied (FTC, Health Products Compliance Guidance).

One public memory case involved a different product, Prevagen, which has no link to Memodyne. The FTC and the New York Attorney General sued over its memory claims, and in December 2024 a federal court ordered the company to stop the misleading claims (FTC, Prevagen complaint (business blog)) (FTC, Statement on win against Prevagen makers).

We include it as a yardstick and nothing more. It shows what regulators expect from any brain claim: evidence that fits the dose and the formula being sold.

A randomized, placebo-controlled trial of the finished capsule, at the label dose, in adults like those who buy it, measuring memory or focus with a named test, and published with the methods. Even one such trial would be news.

We would also want the basics a careful buyer needs: a named manufacturer, a public certificate of analysis for a lot, and one clear refund rule. All three are not published today.

Until then, the safest wording is the plain one. No study supports the memory and focus claims, and no study contradicts them either, because none was done.

Our view: the fact check ends where it began. Research on single ingredients exists, and it answers other questions at much larger doses. Research on Memodyne does not exist.

That is not a verdict of failure. It is a gap, and a buyer should know it is there. Treat the label claims as marketing wording the law allows, treat the sales page as an ad, and treat your own careful log as the only data about you that matters.

Last updated October 29, 2026. Medically reviewed by Dr. Harald Hampel, MD, PhD, MD, Physician, October 16, 2026.